<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Sacituzumab govitecan: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Sacituzumab govitecan: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Sacituzumab govitecan: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="128023" href="/d/html/128023.html" rel="external">see "Sacituzumab govitecan: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="block black-box-warn drugH1Div" id="F54338118"><span class="drugH1">ALERT: US Boxed Warning</span>
<div class="collapsible">
<span class="collapsible-title">Neutropenia:</span>
<div class="collapsible-wrap">
<p style="text-indent:0em;margin-left:2em;">Severe or life-threatening neutropenia may occur. Withhold sacituzumab govitecan for ANC &lt;1,500/mm<sup>3</sup> or neutropenic fever. Monitor blood cell counts periodically during treatment. Consider granulocyte-colony stimulating factor (G-CSF) for secondary prophylaxis. Initiate anti-infective treatment in patients with febrile neutropenia without delay.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Diarrhea:</span>
<div class="collapsible-wrap">
<p style="text-indent:0em;margin-left:2em;">Severe diarrhea may occur. Monitor patients with diarrhea and give fluid and electrolytes as needed. At the onset of diarrhea, evaluate for infectious causes and, if negative, promptly initiate loperamide. If severe diarrhea occurs, withhold sacituzumab govitecan until resolved to ≤ grade 1 and reduce subsequent doses.</p></div>
</div>
</div>
<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F54348880"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Trodelvy</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F56425185"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Trodelvy</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F54338121"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Antineoplastic Agent, Anti-Trop-2;</li>
<li>
                        Antineoplastic Agent, Antibody Drug Conjugate;</li>
<li>
                        Antineoplastic Agent, Monoclonal Antibody;</li>
<li>
                        Antineoplastic Agent, Topoisomerase I Inhibitor</li></ul></div>
<div class="block doa drugH1Div" id="F54363792"><span class="drugH1">Dosing: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Note: </b>Do not substitute sacituzumab govitecan for (or use with) other medications containing irinotecan or its active metabolite SN-38. Calculate the required dose based on the patient's body weight at the beginning of each treatment cycle (or more frequently if the patient's body weight changed by &gt;10% from the previous dose). Withhold sacituzumab govitecan dose on day 1 of any cycle for ANC &lt;1,500/mm<sup>3</sup>; withhold dose on day 8 of any cycle for ANC &lt;1,000/mm<sup>3</sup>.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Premedications: </i>Premedicate with antipyretics and H<sub>1</sub>/H<sub>2</sub> antagonists prior to sacituzumab govitecan infusion; corticosteroids may be used if prior infusion-related reactions occurred. Sacituzumab govitecan is associated with a moderate to high emetic potential; antiemetics (either a 2 or 3 drug combination regimen) are recommended to prevent nausea and vomiting. Patients should be provided take home medications with clear instructions for nausea and vomiting prevention and treatment.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="3d45b69a-c4d5-4984-95fd-5e72b6eeaf31">Breast cancer, triple negative, locally advanced or metastatic, relapsed or refractory</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Breast cancer, triple negative, locally advanced or metastatic, relapsed or refractory: IV:</b> 10 mg/kg on days 1 and 8 of a 21-day treatment cycle (maximum: 10 mg/kg/dose); continue until disease progression or unacceptable toxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33882206','lexi-content-ref-30786188']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33882206','lexi-content-ref-30786188'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="cd2f9554-e897-4b87-b856-03b43a4df846">Breast cancer, locally advanced or metastatic, hormone receptor–positive, HER2-negative</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Breast cancer, locally advanced or metastatic, hormone receptor–positive, HER2-negative: IV:</b> 10 mg/kg on days 1 and 8 of a 21-day treatment cycle (maximum: 10 mg/kg/dose); continue until disease progression or unacceptable toxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-36027558','lexi-content-ref-37633306']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-36027558','lexi-content-ref-37633306'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="a1561b68-4de4-4f0a-9e05-23c88c54b83a">Urothelial cancer, locally advanced or metastatic</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Urothelial cancer, locally advanced or metastatic: IV: </b>10 mg/kg on days 1 and 8 of a 21-day treatment cycle (maximum: 10 mg/kg/dose); continue until disease progression or unacceptable toxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33929895']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33929895'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F54363794"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:-4em;margin-left:4em;">CrCl &gt;30 mL/minute: There are no dosage adjustments provided in the manufacturer's labeling; however, renal elimination of SN-38 (small molecule moiety of sacituzumab govitecan) is minimal.</p>
<p style="text-indent:-4em;margin-left:4em;">CrCl ≤30 mL/minute: There are no dosage adjustments provided in the manufacturer's labeling (no data are available).</p>
<p style="text-indent:-4em;margin-left:4em;">End-stage renal disease: There are no dosage adjustments provided in the manufacturer's labeling (no data are available).</p></div>
<div class="block doha drugH1Div" id="F54363795"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">Total bilirubin ≤ ULN with AST &gt; ULN <b>or</b> bilirubin &gt;1 to 1.5 times ULN with any AST: No initial dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:2em;">Total bilirubin &gt;1.5 times ULN, <b>or</b> AST and ALT &gt;3 times ULN without liver metastases, <b>or</b> AST and ALT &gt;5 times ULN with liver metastases: There are no dosage adjustments provided in the manufacturer's labeling (no initial dosage recommendation can be made).</p></div>
<div class="block doo drugH1Div" id="F57506831"><span class="drugH1">Dosing: Obesity: Adult</span>
<p style="text-indent:0em;display:inline">
<i>American Society of Clinical Oncology guidelines for appropriate systemic therapy dosing in adults with cancer with a BMI ≥30 kg/m<sup>2</sup>:</i> Utilize patient's actual body weight for calculation of BSA- or weight-based dosing; manage regimen-related toxicities in the same manner as for patients with a BMI &lt;30 kg/m<sup>2 </sup>(<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33939491']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33939491'])">Ref</a></span>).</p></div>
<div class="block dot drugH1Div" id="F54368229"><span class="drugH1">Dosing: Adjustment for Toxicity: Adult</span>
<table border="1" frame="border" rules="all">
<caption>
<b>Sacituzumab Govitecan Dosage Adjustments for Adverse Reactions<sup>a</sup></b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead valign="middle">
<tr>
<th align="center">
<p style="text-indent:0em;">
<b>Adverse Reaction</b></p></th>
<th align="center">
<p style="text-indent:0em;">
<b>Occurrence</b></p></th>
<th align="center">
<p style="text-indent:0em;">
<b>Dose Modification<sup>a</sup></b></p></th></tr></thead>
<tfoot valign="middle">
<tr>
<td align="center" colspan="3">
<p style="text-indent:0em;text-align:left;">
<sup>a </sup>Do not re-escalate the sacituzumab govitecan dose after a dose reduction for adverse reactions.</p></td></tr>
<tr>
<td align="center" colspan="3">
<p style="text-indent:0em;text-align:left;">
<sup>b </sup>Administer G-CSF as clinically indicated.</p></td></tr>
<tr>
<td align="center" colspan="3">
<p style="text-indent:0em;text-align:left;">
<sup>c</sup> G-CSF = granulocyte-colony stimulating factor.</p></td></tr></tfoot>
<tbody valign="middle">
<tr>
<td align="center" colspan="3">
<p style="text-indent:0em;text-align:left;">
<b>Hematologic toxicity<sup>b</sup></b></p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">ANC &lt;1,500/mm<sup>3</sup></p></td>
<td align="center">
<p style="text-indent:0em;">Day 1 of any cycle</p></td>
<td align="center">
<p style="text-indent:0em;">Withhold sacituzumab govitecan.</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">ANC &lt;1,000/mm<sup>3</sup></p></td>
<td align="center">
<p style="text-indent:0em;">Day 8 of any cycle</p></td>
<td align="center">
<p style="text-indent:0em;">Withhold sacituzumab govitecan.</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">Neutropenic fever</p></td>
<td align="center">
<p style="text-indent:0em;">Any</p></td>
<td align="center">
<p style="text-indent:0em;">Withhold sacituzumab govitecan.</p></td></tr>
<tr>
<td align="center" rowspan="3">
<p style="text-indent:0em;">Grade 4 neutropenia (ANC &lt;500/mm<sup>3</sup>) lasting ≥7 days</p>
<p style="text-indent:0em;">OR</p>
<p style="text-indent:0em;">Grade 3 or 4 neutropenic fever (ANC &lt;1,000/mm<sup>3</sup> and fever ≥38.5°C)</p>
<p style="text-indent:0em;">OR</p>
<p style="text-indent:0em;">On day of scheduled sacituzumab govitecan dose, grade 3 or 4 neutropenia, which delays dosing by 2 or 3 weeks for recovery to ≤ grade 1</p></td>
<td align="center">
<p style="text-indent:0em;">First</p></td>
<td align="center">
<p style="text-indent:0em;">Reduce sacituzumab govitecan dose by 25% and administer G-CSF<sup>c</sup> support.</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">Second</p></td>
<td align="center">
<p style="text-indent:0em;">Reduce sacituzumab govitecan dose by 50% and administer G-CSF.</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">Third</p></td>
<td align="center">
<p style="text-indent:0em;">Discontinue sacituzumab govitecan and administer G-CSF.</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">On day of scheduled sacituzumab govitecan dose, grade 3 or 4 neutropenia, which delays dosing beyond 3 weeks for recovery to ≤ grade 1</p></td>
<td align="center">
<p style="text-indent:0em;">First</p></td>
<td align="center">
<p style="text-indent:0em;">Discontinue sacituzumab govitecan and administer G-CSF.</p></td></tr>
<tr>
<td align="center" rowspan="3">
<p style="text-indent:0em;">On day of scheduled sacituzumab govitecan dose, grade 3 or 4 non-neutropenic hematologic toxicity, which delays dosing by 2 or 3 weeks for recovery to ≤ grade 1</p></td>
<td align="center">
<p style="text-indent:0em;">First</p></td>
<td align="center">
<p style="text-indent:0em;">Reduce sacituzumab govitecan dose by 25%.</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">Second</p></td>
<td align="center">
<p style="text-indent:0em;">Reduce sacituzumab govitecan dose by 50%.</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">Third</p></td>
<td align="center">
<p style="text-indent:0em;">Discontinue sacituzumab govitecan.</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">Grade 3 or 4 non-neutropenic hematologic toxicity, which does not recover to ≤ grade 1 within 3 weeks</p></td>
<td align="center">
<p style="text-indent:0em;">First</p></td>
<td align="center">
<p style="text-indent:0em;">Discontinue sacituzumab govitecan.</p></td></tr>
<tr>
<td align="center" colspan="3">
<p style="text-indent:0em;text-align:left;">
<b>Nonhematologic toxicity</b></p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">GI toxicity: Diarrhea (grade 3 or 4)</p></td>
<td align="center">
<p style="text-indent:0em;">Occurring at the time of a scheduled dose</p></td>
<td align="center">
<p style="text-indent:0em;">Withhold sacituzumab govitecan; resume when diarrhea has resolved to ≤ grade 1. Evaluate for infectious causes at onset of diarrhea. If negative, initiate loperamide 4 mg initially, followed by 2 mg with every diarrhea episode up to a maximum of 16 mg/day (discontinue loperamide 12 hours after diarrhea resolves). Initiate additional supportive measures (fluids, electrolytes) as clinically indicated. If an excessive cholinergic response occurs, may consider appropriate anticholinergic (eg, atropine) premedication with subsequent infusions.</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">GI toxicity: Nausea (grade 3) or vomiting (grade 3 or 4)</p></td>
<td align="center">
<p style="text-indent:0em;">Occurring at the time of a scheduled dose</p></td>
<td align="center">
<p style="text-indent:0em;">Withhold sacituzumab govitecan; resume with additional supportive measures when resolved to ≤ grade 1.</p></td></tr>
<tr>
<td align="center" rowspan="3">
<p style="text-indent:0em;">GI toxicity: Any grade 3 or 4 nausea, vomiting, or diarrhea due to sacituzumab govitecan that is not controlled with antiemetics and/or antidiarrheal treatment</p></td>
<td align="center">
<p style="text-indent:0em;">First</p></td>
<td align="center">
<p style="text-indent:0em;">Reduce sacituzumab govitecan dose by 25%.</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">Second</p></td>
<td align="center">
<p style="text-indent:0em;">Reduce sacituzumab govitecan dose by 50%.</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">Third</p></td>
<td align="center">
<p style="text-indent:0em;">Discontinue sacituzumab govitecan.</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">Hypersensitivity</p></td>
<td align="center"></td>
<td align="center">
<p style="text-indent:0em;">May require permanent discontinuation.</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">Infusion-related reaction</p></td>
<td align="center"></td>
<td align="center">
<p style="text-indent:0em;">Slow or interrupt the sacituzumab govitecan infusion if an infusion-related reaction occurs. Permanently discontinue sacituzumab govitecan for grade 4 or life-threatening infusion-related reactions.</p></td></tr>
<tr>
<td align="center" rowspan="3">
<p style="text-indent:0em;">Grade 4 nonhematologic toxicity of any duration</p>
<p style="text-indent:0em;">OR</p>
<p style="text-indent:0em;">Other grade 3 or 4 nonhematologic toxicity lasting &gt;48 hours (despite optimal medical management)</p>
<p style="text-indent:0em;">OR</p>
<p style="text-indent:0em;">On day of scheduled sacituzumab govitecan dose, grade 3 or 4 nonhematologic toxicity, which delays dosing by 2 or 3 weeks for recovery to ≤ grade 1</p></td>
<td align="center">
<p style="text-indent:0em;">First</p></td>
<td align="center">
<p style="text-indent:0em;">Reduce sacituzumab govitecan dose by 25%.</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">Second</p></td>
<td align="center">
<p style="text-indent:0em;">Reduce sacituzumab govitecan dose by 50%.</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">Third</p></td>
<td align="center">
<p style="text-indent:0em;">Discontinue sacituzumab govitecan.</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">Grade 3 or 4 nonhematologic toxicity, which does not recover to ≤ grade 1 within 3 weeks</p></td>
<td align="center">
<p style="text-indent:0em;">First</p></td>
<td align="center">
<p style="text-indent:0em;">Discontinue sacituzumab govitecan.</p></td></tr></tbody></table></div>
<div class="block doe drugH1Div" id="F54363793"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block arsc drugH1Div" id="F54504726"><span class="drugH1">Adverse Reactions (Significant): Considerations</span>
<div class="collapsible">
<span class="collapsible-title">Bone marrow suppression</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Sacituzumab govitecan may cause <b>neutropenia,</b> including grades 3 and 4 and <b>febrile neutropenia</b>. Anemia, <b>leukopenia</b>, <b>lymphocytopenia</b>, and thrombocytopenia have also been reported. Neutropenia was the most common adverse reaction leading to treatment interruption in clinical trials.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism: </i>Exact mechanism is unknown; SN-38 is the active metabolite of the cytotoxic agent irinotecan, a topoisomerase I inhibitor.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> May occur at any time during treatment, including during the first cycle (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28558150']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28558150'])">Ref</a></span>). Median onset of 16 days has been reported for neutropenia.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Patients who are homozygous for the UGT1A1*28 allele; <b>Note: </b>Toxic effects of irinotecan (of which, SN-38 is the active metabolite) have been associated with UGT1A1*28 homozygosity. Clinical trials of sacituzumab govitecan showed a numerically increased incidence of neutropenia in patients with a UGT1A1*28 genotype compared to *1/*28 or *1/*1 (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30786188','lexi-content-ref-31584574']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30786188','lexi-content-ref-31584574'])">Ref</a></span>). Additional validation is needed prior to use of genetic testing for clinical decision making related to use of sacituzumab govitecan (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30786188']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30786188'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">GI toxicity</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Sacituzumab govitecan may cause <b>diarrhea,</b> including grades 3 and 4 <b>diarrhea</b>; permanent discontinuation due to diarrhea occurred rarely in clinical trials. <b>Colitis</b> and <b>neutropenic enterocolitis </b>have been reported rarely. Other GI adverse reactions may include <b>abdominal pain, dyspepsia, </b>and<b> stomatitis</b>. Abdominal cramps and increased salivation have also been reported in patients who experience an excessive cholinergic response to treatment.</p>
<p style="text-indent:-2em;margin-left:4em;">Sacituzumab govitecan is associated with moderate to high emetic potential and may cause <b>nausea</b> and <b>vomiting</b> (including grades 3 and 4); premeditation and/or treatment interruption may be required.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Dose-related; related to the pharmacologic action. SN-38 is the active metabolite of the cytotoxic agent irinotecan, a topoisomerase I inhibitor. When compared to irinotecan, sacituzumab govitecan results in lower concentrations of the glucuronidated form of SN-38 which may explain the lower incidence of diarrhea (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30786188','lexi-content-ref-31584574']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30786188','lexi-content-ref-31584574'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Hypersensitivity</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Sacituzumab govitecan may cause <b>hypersensitivity reactions</b>, including severe and life-threatening reactions; <b>anaphylaxis</b> has rarely been reported.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset: </i>Rapid; reported within 24 hours of administration in over one-third of patients.</p></div>
</div>
</div>
<div class="block adr drugH1Div" id="F54347117"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Adverse reactions reported in adults.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Edema (17% to 19%)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Alopecia (38% to 49%), pruritus (10% to 17%), skin rash (12% to 32%), xeroderma (15%)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Decreased serum albumin (32% to 51%), decreased serum glucose (10% to 19%), decreased serum magnesium (18% to 51%), decreased serum phosphate (17% to 41%), decreased serum potassium (22% to 33%), dehydration (13%; severe dehydration: 2%), increased lactate dehydrogenase (16% to 28%), increased serum albumin (32%), increased serum glucose (31% to 59%), increased serum phosphate (16%), increased serum potassium (14%), weight loss (17%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal pain (20% to 31%; severe abdominal pain: 2%), constipation (34% to 37%), decreased appetite (21% to 41%; including anorexia), diarrhea (59% to 72%; grades 3/4: 9% to 12%)<span class="lexi-table-link-container"> (<a aria-label="Diarrhea table link" class="lexi-table-link" data-table-id="lexi-content-diarrhea" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-diarrhea')">table 1</a>)</span><span class="table-link" style="display:none;">Diarrhea</span>, dysgeusia (11%), dyspepsia (11%), nausea (57% to 69%; grades 3/4: 3% to 6%)<span class="lexi-table-link-container"> (<a aria-label="Nausea table link" class="lexi-table-link" data-table-id="lexi-content-nausea" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-nausea')">table 2</a>)</span><span class="table-link" style="display:none;">Nausea</span>, stomatitis (14% to 17%; grades 3/4: 1% to 2%), vomiting (23% to 49%; grades 3/4: 1% to 6%)<span class="lexi-table-link-container"> (<a aria-label="Vomiting table link" class="lexi-table-link" data-table-id="lexi-content-vomiting" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-vomiting')">table 3</a>)</span><span class="table-link" style="display:none;">Vomiting</span></p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Diarrhea" frame="border" id="lexi-content-diarrhea" rules="all">
<caption style="text-align:center;">
<b>Sacituzumab Govitecan: Adverse Reaction: Diarrhea</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Sacituzumab Govitecan)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Comparator (Single Agent Chemotherapy)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Sacituzumab Govitecan)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Comparator)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">All grades: 62%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">All grades: 23%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Locally advanced or metastatic HR-positive, HER2-negative breast cancer</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">268</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">249</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">Grades 3/4: 10%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Grades 3/4: 1%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Locally advanced or metastatic HR-positive, HER2-negative breast cancer</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">268</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">249</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">All grades: 72%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Locally advanced or metastatic urothelial cancer</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">113</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">Grades 3/4: 12%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Locally advanced or metastatic urothelial cancer</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">113</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">All grades: 63%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Metastatic triple-negative breast cancer</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">108</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">Grades 3/4: 9%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Metastatic triple-negative breast cancer</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">108</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">All grades: 59%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">All grades: 17%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Metastatic triple-negative breast cancer</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">258</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">224</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">Grades 3/4: 11%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Grades 3/4: 1%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Metastatic triple-negative breast cancer</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">258</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">224</p></td></tr></tbody></table>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Nausea" frame="border" id="lexi-content-nausea" rules="all">
<caption style="text-align:center;">
<b>Sacituzumab Govitecan: Adverse Reaction: Nausea</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead valign="top">
<tr>
<th align="left">
<p style="text-indent:0em;">
<b>Drug (Sacituzumab Govitecan)</b></p></th>
<th align="left">
<p style="text-indent:0em;">
<b>Comparator (Single agent chemotherapy)</b></p></th>
<th align="left">
<p style="text-indent:0em;">
<b>Indication</b></p></th>
<th align="left">
<p style="text-indent:0em;">
<b>Number of Patients (Sacituzumab Govitecan)</b></p></th>
<th align="left">
<p style="text-indent:0em;">
<b>Number of Patients (Comparator)</b></p></th></tr></thead>
<tbody valign="top">
<tr>
<td align="left">
<p style="text-indent:0em;">59%</p></td>
<td align="left">
<p style="text-indent:0em;">35%</p></td>
<td align="left">
<p style="text-indent:0em;">Locally advanced or metastatic HR-positive, HER2-negative breast cancer</p></td>
<td align="left">
<p style="text-indent:0em;">268</p></td>
<td align="left">
<p style="text-indent:0em;">249</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">All grades: 66%</p></td>
<td align="left">
<p style="text-indent:0em;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;">Locally advanced or metastatic urothelial cancer</p></td>
<td align="left">
<p style="text-indent:0em;">113</p></td>
<td align="left">
<p style="text-indent:0em;">N/A</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">Grades 3/4: 4%</p></td>
<td align="left">
<p style="text-indent:0em;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;">Locally advanced or metastatic urothelial cancer</p></td>
<td align="left">
<p style="text-indent:0em;">113</p></td>
<td align="left">
<p style="text-indent:0em;">N/A</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">All grades: 69%</p></td>
<td align="left">
<p style="text-indent:0em;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;">Metastatic triple-negative breast cancer</p></td>
<td align="left">
<p style="text-indent:0em;">108</p></td>
<td align="left">
<p style="text-indent:0em;">N/A</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">Grades 3/4: 6%</p></td>
<td align="left">
<p style="text-indent:0em;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;">Metastatic triple-negative breast cancer</p></td>
<td align="left">
<p style="text-indent:0em;">108</p></td>
<td align="left">
<p style="text-indent:0em;">N/A</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">All grades: 57%</p></td>
<td align="left">
<p style="text-indent:0em;">All grades: 26%</p></td>
<td align="left">
<p style="text-indent:0em;">Metastatic triple-negative breast cancer</p></td>
<td align="left">
<p style="text-indent:0em;">258</p></td>
<td align="left">
<p style="text-indent:0em;">224</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">Grades 3/4: 3%</p></td>
<td align="left">
<p style="text-indent:0em;">Grades 3/4: 0.4%</p></td>
<td align="left">
<p style="text-indent:0em;">Metastatic triple-negative breast cancer</p></td>
<td align="left">
<p style="text-indent:0em;">258</p></td>
<td align="left">
<p style="text-indent:0em;">224</p></td></tr></tbody></table>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Vomiting" frame="border" id="lexi-content-vomiting" rules="all">
<caption style="text-align:center;">
<b>Sacituzumab Govitecan: Adverse Reaction: Vomiting</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead valign="top">
<tr>
<th align="left">
<p style="text-indent:0em;">
<b>Drug (Sacituzumab Govitecan)</b></p></th>
<th align="left">
<p style="text-indent:0em;">
<b>Comparator (Single agent chemotherapy)</b></p></th>
<th align="left">
<p style="text-indent:0em;">
<b>Indication</b></p></th>
<th align="left">
<p style="text-indent:0em;">
<b>Number of Patients (Sacituzumab Govitecan)</b></p></th>
<th align="left">
<p style="text-indent:0em;">
<b>Number of Patients (Comparator)</b></p></th></tr></thead>
<tbody valign="top">
<tr>
<td align="left">
<p style="text-indent:0em;">23%</p></td>
<td align="left">
<p style="text-indent:0em;">16%</p></td>
<td align="left">
<p style="text-indent:0em;">Locally advanced or metastatic HR-positive, HER2-negative breast cancer</p></td>
<td align="left">
<p style="text-indent:0em;">268</p></td>
<td align="left">
<p style="text-indent:0em;">249</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">All grades: 34%</p></td>
<td align="left">
<p style="text-indent:0em;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;">Locally advanced or metastatic urothelial cancer</p></td>
<td align="left">
<p style="text-indent:0em;">113</p></td>
<td align="left">
<p style="text-indent:0em;">N/A</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">Grades 3/4: 1%</p></td>
<td align="left">
<p style="text-indent:0em;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;">Locally advanced or metastatic urothelial cancer</p></td>
<td align="left">
<p style="text-indent:0em;">113</p></td>
<td align="left">
<p style="text-indent:0em;">N/A</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">All grades: 49%</p></td>
<td align="left">
<p style="text-indent:0em;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;">Metastatic triple-negative breast cancer</p></td>
<td align="left">
<p style="text-indent:0em;">108</p></td>
<td align="left">
<p style="text-indent:0em;">N/A</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">Grades 3/4: 6%</p></td>
<td align="left">
<p style="text-indent:0em;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;">Metastatic triple-negative breast cancer</p></td>
<td align="left">
<p style="text-indent:0em;">108</p></td>
<td align="left">
<p style="text-indent:0em;">N/A</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">All grades: 33%</p></td>
<td align="left">
<p style="text-indent:0em;">All grades: 16%</p></td>
<td align="left">
<p style="text-indent:0em;">Metastatic triple-negative breast cancer</p></td>
<td align="left">
<p style="text-indent:0em;">258</p></td>
<td align="left">
<p style="text-indent:0em;">224</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">Grades 3/4: 2%</p></td>
<td align="left">
<p style="text-indent:0em;">Grades 3/4: 1%</p></td>
<td align="left">
<p style="text-indent:0em;">Metastatic triple-negative breast cancer</p></td>
<td align="left">
<p style="text-indent:0em;">258</p></td>
<td align="left">
<p style="text-indent:0em;">224</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Hematuria (16%), urinary tract infection (13% to 21%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Decreased hemoglobin (71% to 94%; grades 3/4: 6% to 18%), decreased platelet count (21% to 30%; grades 3/4: 1% to 3%)<span class="lexi-table-link-container"> (<a aria-label="Decreased Hemoglobin table link" class="lexi-table-link" data-table-id="lexi-content-decreased-hemoglobin" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-decreased-hemoglobin')">table 4</a>)</span><span class="table-link" style="display:none;">Decreased Hemoglobin</span>, decreased neutrophils (67% to 83%; grades 3/4: 32% to 53%)<span class="lexi-table-link-container"> (<a aria-label="Decreased Neutrophils table link" class="lexi-table-link" data-table-id="lexi-content-decreased-neutrophils" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-decreased-neutrophils')">table 5</a>)</span><span class="table-link" style="display:none;">Decreased Neutrophils</span>, eosinophilia (13%), leukopenia (78% to 91%, grades 3/4: 26% to 41%)<span class="lexi-table-link-container"> (<a aria-label="Leukopenia table link" class="lexi-table-link" data-table-id="lexi-content-leukopenia" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-leukopenia')">table 6</a>)</span><span class="table-link" style="display:none;">Leukopenia</span>, lymphocytopenia (65% to 88%; grades 3/4: 21% to 35%), prolonged partial thromboplastin time (33% to 60%; grades 3/4: 6% to 12%)</p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Decreased Hemoglobin" frame="border" id="lexi-content-decreased-hemoglobin" rules="all">
<caption style="text-align:center;">
<b>Sacituzumab Govitecan: Adverse Reaction: Decreased Hemoglobin</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead valign="top">
<tr>
<th align="left">
<p style="text-indent:0em;">
<b>Drug (Sacituzumab Govitecan)</b></p></th>
<th align="left">
<p style="text-indent:0em;">
<b>Comparator (Single agent chemotherapy)</b></p></th>
<th align="left">
<p style="text-indent:0em;">
<b>Indication</b></p></th>
<th align="left">
<p style="text-indent:0em;">
<b>Number of Patients (Sacituzumab Govitecan)</b></p></th>
<th align="left">
<p style="text-indent:0em;">
<b>Number of Patients (Comparator)</b></p></th></tr></thead>
<tbody valign="top">
<tr>
<td align="left">
<p style="text-indent:0em;">All grades: 73%</p></td>
<td align="left">
<p style="text-indent:0em;">All grades: 59%</p></td>
<td align="left">
<p style="text-indent:0em;">Locally advanced or metastatic HR-positive, HER2-negative breast cancer</p></td>
<td align="left">
<p style="text-indent:0em;">268</p></td>
<td align="left">
<p style="text-indent:0em;">249</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">Grades 3/4: 8%</p></td>
<td align="left">
<p style="text-indent:0em;">Grades 3/4: 5%</p></td>
<td align="left">
<p style="text-indent:0em;">Locally advanced or metastatic HR-positive, HER2-negative breast cancer</p></td>
<td align="left">
<p style="text-indent:0em;">268</p></td>
<td align="left">
<p style="text-indent:0em;">249</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">All grades: 71%</p></td>
<td align="left">
<p style="text-indent:0em;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;">Locally advanced or metastatic urothelial cancer</p></td>
<td align="left">
<p style="text-indent:0em;">113</p></td>
<td align="left">
<p style="text-indent:0em;">N/A</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">Grades 3/4: 18%</p></td>
<td align="left">
<p style="text-indent:0em;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;">Locally advanced or metastatic urothelial cancer</p></td>
<td align="left">
<p style="text-indent:0em;">113</p></td>
<td align="left">
<p style="text-indent:0em;">N/A</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">All grades: 94%</p></td>
<td align="left">
<p style="text-indent:0em;">All grades: 57%</p></td>
<td align="left">
<p style="text-indent:0em;">Metastatic triple-negative breast cancer</p></td>
<td align="left">
<p style="text-indent:0em;">258</p></td>
<td align="left">
<p style="text-indent:0em;">224</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">Grades 3/4: 9%</p></td>
<td align="left">
<p style="text-indent:0em;">Grades 3/4: 6%</p></td>
<td align="left">
<p style="text-indent:0em;">Metastatic triple-negative breast cancer</p></td>
<td align="left">
<p style="text-indent:0em;">258</p></td>
<td align="left">
<p style="text-indent:0em;">224</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">All grades: 93%</p></td>
<td align="left">
<p style="text-indent:0em;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;">Metastatic triple-negative breast cancer</p></td>
<td align="left">
<p style="text-indent:0em;">108</p></td>
<td align="left">
<p style="text-indent:0em;">N/A</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">Grades 3/4: 6%</p></td>
<td align="left">
<p style="text-indent:0em;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;">Metastatic triple-negative breast cancer</p></td>
<td align="left">
<p style="text-indent:0em;">108</p></td>
<td align="left">
<p style="text-indent:0em;">N/A</p></td></tr></tbody></table>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Decreased Neutrophils" frame="border" id="lexi-content-decreased-neutrophils" rules="all">
<caption style="text-align:center;">
<b>Sacituzumab Govitecan: Adverse Reaction: Decreased Neutrophils</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead valign="top">
<tr>
<th align="left">
<p style="text-indent:0em;">
<b>Drug (Sacituzumab Govitecan)</b></p></th>
<th align="left">
<p style="text-indent:0em;">
<b>Comparator (Single agent chemotherapy)</b></p></th>
<th align="left">
<p style="text-indent:0em;">
<b>Indication</b></p></th>
<th align="left">
<p style="text-indent:0em;">
<b>Number of Patients (Sacituzumab Govitecan)</b></p></th>
<th align="left">
<p style="text-indent:0em;">
<b>Number of Patients (Comparator)</b></p></th></tr></thead>
<tbody valign="top">
<tr>
<td align="left">
<p style="text-indent:0em;">All grades: 83%</p></td>
<td align="left">
<p style="text-indent:0em;">All grades: 67%</p></td>
<td align="left">
<p style="text-indent:0em;">Locally advanced or metastatic HR-positive, HER2-negative breast cancer</p></td>
<td align="left">
<p style="text-indent:0em;">268</p></td>
<td align="left">
<p style="text-indent:0em;">249</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">Grades 3/4: 53%</p></td>
<td align="left">
<p style="text-indent:0em;">Grades 3/4: 40%</p></td>
<td align="left">
<p style="text-indent:0em;">Locally advanced or metastatic HR-positive, HER2-negative breast cancer</p></td>
<td align="left">
<p style="text-indent:0em;">268</p></td>
<td align="left">
<p style="text-indent:0em;">249</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">All grades: 67%</p></td>
<td align="left">
<p style="text-indent:0em;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;">Locally advanced or metastatic urothelial cancer</p></td>
<td align="left">
<p style="text-indent:0em;">113</p></td>
<td align="left">
<p style="text-indent:0em;">N/A</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">Grades 3/4: 43%</p></td>
<td align="left">
<p style="text-indent:0em;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;">Locally advanced or metastatic urothelial cancer</p></td>
<td align="left">
<p style="text-indent:0em;">113</p></td>
<td align="left">
<p style="text-indent:0em;">N/A</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">All grades: 78%</p></td>
<td align="left">
<p style="text-indent:0em;">All grades: 48%</p></td>
<td align="left">
<p style="text-indent:0em;">Metastatic triple-negative breast cancer</p></td>
<td align="left">
<p style="text-indent:0em;">258</p></td>
<td align="left">
<p style="text-indent:0em;">224</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">Grades 3/4: 49%</p></td>
<td align="left">
<p style="text-indent:0em;">Grades 3/4: 36%</p></td>
<td align="left">
<p style="text-indent:0em;">Metastatic triple-negative breast cancer</p></td>
<td align="left">
<p style="text-indent:0em;">258</p></td>
<td align="left">
<p style="text-indent:0em;">224</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">All grades: 82%</p></td>
<td align="left">
<p style="text-indent:0em;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;">Metastatic triple-negative breast cancer</p></td>
<td align="left">
<p style="text-indent:0em;">108</p></td>
<td align="left">
<p style="text-indent:0em;">N/A</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">Grades 3/4: 32%</p></td>
<td align="left">
<p style="text-indent:0em;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;">Metastatic triple-negative breast cancer</p></td>
<td align="left">
<p style="text-indent:0em;">108</p></td>
<td align="left">
<p style="text-indent:0em;">N/A</p></td></tr></tbody></table>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Leukopenia" frame="border" id="lexi-content-leukopenia" rules="all">
<caption style="text-align:center;">
<b>Sacituzumab Govitecan: Adverse Reaction: Leukopenia</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead valign="top">
<tr>
<th align="left">
<p style="text-indent:0em;">
<b>Drug (Sacituzumab Govitecan)</b></p></th>
<th align="left">
<p style="text-indent:0em;">
<b>Comparator (Single agent chemotherapy)</b></p></th>
<th align="left">
<p style="text-indent:0em;">
<b>Indication</b></p></th>
<th align="left">
<p style="text-indent:0em;">
<b>Number of Patients (Sacituzumab Govitecan)</b></p></th>
<th align="left">
<p style="text-indent:0em;">
<b>Number of Patients (Comparator)</b></p></th></tr></thead>
<tbody valign="top">
<tr>
<td align="left">
<p style="text-indent:0em;">All grades: 88%</p></td>
<td align="left">
<p style="text-indent:0em;">All grades: 73%</p></td>
<td align="left">
<p style="text-indent:0em;">Locally advanced or metastatic HR-positive, HER2-negative breast cancer</p></td>
<td align="left">
<p style="text-indent:0em;">268</p></td>
<td align="left">
<p style="text-indent:0em;">249</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">Grades 3/4: 38%</p></td>
<td align="left">
<p style="text-indent:0em;">Grades 3/4: 26%</p></td>
<td align="left">
<p style="text-indent:0em;">Locally advanced or metastatic HR-positive, HER2-negative breast cancer</p></td>
<td align="left">
<p style="text-indent:0em;">268</p></td>
<td align="left">
<p style="text-indent:0em;">249</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">All grades: 78%</p></td>
<td align="left">
<p style="text-indent:0em;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;">Locally advanced or metastatic urothelial cancer</p></td>
<td align="left">
<p style="text-indent:0em;">113</p></td>
<td align="left">
<p style="text-indent:0em;">N/A</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">Grades 3/4: 38%</p></td>
<td align="left">
<p style="text-indent:0em;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;">Locally advanced or metastatic urothelial cancer</p></td>
<td align="left">
<p style="text-indent:0em;">113</p></td>
<td align="left">
<p style="text-indent:0em;">N/A</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">All grades: 86%</p></td>
<td align="left">
<p style="text-indent:0em;">All grades: 53%</p></td>
<td align="left">
<p style="text-indent:0em;">Metastatic triple-negative breast cancer</p></td>
<td align="left">
<p style="text-indent:0em;">258</p></td>
<td align="left">
<p style="text-indent:0em;">224</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">Grades 3/4: 41%</p></td>
<td align="left">
<p style="text-indent:0em;">Grades 3/4: 25%</p></td>
<td align="left">
<p style="text-indent:0em;">Metastatic triple-negative breast cancer</p></td>
<td align="left">
<p style="text-indent:0em;">258</p></td>
<td align="left">
<p style="text-indent:0em;">224</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">All grades: 91%</p></td>
<td align="left">
<p style="text-indent:0em;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;">Metastatic triple-negative breast cancer</p></td>
<td align="left">
<p style="text-indent:0em;">108</p></td>
<td align="left">
<p style="text-indent:0em;">N/A</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">Grades 3/4: 26%</p></td>
<td align="left">
<p style="text-indent:0em;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;">Metastatic triple-negative breast cancer</p></td>
<td align="left">
<p style="text-indent:0em;">108</p></td>
<td align="left">
<p style="text-indent:0em;">N/A</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Increased serum alanine aminotransferase (21% to 35%), increased serum alkaline phosphatase (23% to 57%), increased serum aspartate aminotransferase (15% to 45%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Hypersensitivity reaction (35%)</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Infection (50%; serious infection: 18%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Dizziness (10% to 22%), fatigue (57% to 68%; including asthenia), headache (16% to 23%), insomnia (11% to 13%), neuropathy (24%; peripheral neuropathy: 12%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Arthralgia (12% to 17%), back pain (16% to 23%), limb pain (11%)</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Acute kidney injury (24%), decreased creatinine clearance (24%), increased serum creatinine (32%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Cough (12% to 24%), dyspnea (16% to 21%; severe dyspnea: 3%), respiratory tract infection (26%), upper respiratory tract infection (12%)</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever (14% to 19%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Hypotension (5%), venous thromboembolism (9%)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Skin hyperpigmentation (3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Hypocalcemia (3%), hypokalemia (10%), hyponatremia (2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Colitis (including neutropenic enterocolitis: 2%), intestinal obstruction (3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Proteinuria (1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Febrile neutropenia (4% to 10%)</p>
<p style="text-indent:-2em;margin-left:4em;">Immunologic: Antibody development (1%; neutralizing: &lt;1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Bacteremia (≤9%), sepsis (≤9%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Pain (5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Nasal congestion (3%), pleural effusion (2%), pneumonia (2% to 4%), rhinorrhea (5%)</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%:</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Enteritis</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Anaphylaxis</p></div>
<div class="block coi drugH1Div" id="F54338123"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">Severe hypersensitivity to sacituzumab govitecan or any component of the formulation.</p></div>
<div class="block war drugH1Div" id="F54363758"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations: </i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Older age: In some studies, patients ≥65 years of age experienced a higher discontinuation rate due to adverse reactions (compared to patients &lt;65 years of age).</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Dosage form specific issues:</b></i></p>
<p style="text-indent:-2em;margin-left:4em;">• Polysorbate 80: Some dosage forms may contain polysorbate 80 (also known as Tweens). Hypersensitivity reactions, usually a delayed reaction, have been reported following exposure to pharmaceutical products containing polysorbate 80 in certain individuals (Isaksson 2002; Lucente 2000; Shelley 1995). Thrombocytopenia, ascites, pulmonary deterioration, and renal and hepatic failure have been reported in premature neonates after receiving parenteral products containing polysorbate 80 (Alade 1986; CDC 1984). See manufacturer's labeling.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Other warnings/precautions:</b></i></p>
<p style="text-indent:-2em;margin-left:4em;">• Reduced UGT1A1 activity: Patients who are homozygous or heterozygous for the UGT1A1*28 allele may be at increased risk for adverse reactions (compared to wild-type). Early acute-onset or unusually severe adverse reactions may be indicative of reduced UGT1A1 enzyme activity.</p></div>
<div class="block foc drugH1Div" id="F54348881"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Reconstituted, Intravenous [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Trodelvy: Sacituzumab govitecan-hziy 180 mg (1 ea) [contains polysorbate 80]</p></div>
<div class="block geq drugH1Div" id="F54348879"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block fee drugH1Div" id="F54407926"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution (reconstituted)</b> (Trodelvy Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">180 mg (per each): $2,884.63</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F56425186"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Reconstituted, Intravenous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Trodelvy: 180 mg (1 ea) [contains polysorbate 80]</p></div>
<div class="block adm drugH1Div" id="F54368238"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>IV:</b> Administer the initial sacituzumab govitecan infusion over 3 hours; may administer subsequent infusions over 1 to 2 hours if prior infusions were tolerated. Protect infusion bag from light during infusion; however, tubing does not need to be protected from light during infusion and light-protective tubing is not necessary. After infusion is complete, flush infusion line with 20 mL NS. Observe patients during infusion and for at least 30 minutes after each infusion. If more than 1 infusion bag is necessary to administer the full dose, infuse the bags sequentially. Administer infusion within 6 hours (including infusion time) after refrigeration.</p>
<p style="text-indent:-2em;margin-left:2em;">Prior to each dose, premedicate with antipyretics and H<b>
<sub>1</sub></b>/H<b>
<sub>2</sub></b> antagonists; corticosteroids may be administered if an infusion-related reaction occurred with a prior dose. Slow or interrupt the infusion if an infusion-related reaction develops; permanently discontinue for life-threatening infusion-related reactions.</p>
<p style="text-indent:-2em;margin-left:2em;">Sacituzumab govitecan is associated with a moderate to high emetic potential; antiemetics (either a 2 or 3 drug combination regimen) are recommended to prevent nausea and vomiting.</p>
<p style="text-indent:-2em;margin-left:2em;">Do not administer as an IV push or bolus. Do not administer with other medications.</p></div>
<div class="block hazard drugH1Div" id="F54363782"><span class="drugH1">Hazardous Drugs Handling Considerations</span>
<p style="text-indent:0em;">Hazardous agent (NIOSH [group 1]).</p>
<p style="text-indent:0em;margin-top:2em;">Use appropriate precautions for receiving, handling, storage, preparation, dispensing, transporting, administration, and disposal. Follow NIOSH and USP 800 recommendations <b>and</b> institution-specific policies/procedures for appropriate containment strategy (NIOSH 2016; USP-NF 2020).</p></div>
<div class="block use drugH1Div" id="F54338122"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Breast cancer, locally advanced or metastatic:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Treatment of unresectable locally advanced or metastatic triple-negative breast cancer in adults who have received 2 or more prior systemic therapies, at least one of which was for metastatic disease.</p>
<p style="text-indent:-2em;margin-left:4em;">Treatment of unresectable locally advanced or metastatic hormone receptor (HR)–positive, human epidermal growth factor receptor 2 (HER2)–negative (IHC 0, IHC 1+, or IHC 2+/ISH−) breast cancer in adults who have received endocrine-based therapy and at least 2 additional systemic therapies in the metastatic setting.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Urothelial cancer, locally advanced or metastatic:</b> Treatment of locally advanced or metastatic urothelial cancer in adults who have previously received platinum-containing chemotherapy and either programmed death receptor-1 or programmed death-ligand 1 inhibitor.</p></div>
<div class="block mst drugH1Div" id="F54363741"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Sacituzumab govitecan may be confused with fam-trastuzumab deruxtecan, sarilumab, secukinumab.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">High alert medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">This medication is in a class the Institute for Safe Medication Practices includes among its list of drug classes that have a heightened risk of causing significant patient harm when used in error.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Other safety concerns:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Do not substitute sacituzumab govitecan for (or use with) other medications containing irinotecan or its active metabolite SN-38.</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F54367801"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of UGT1A1</p></div>
<div class="block dri drugH1Div" id="F54367798"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">5-Aminosalicylic Acid Derivatives: May enhance the myelosuppressive effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Abrocitinib: May enhance the immunosuppressive effect of Immunosuppressants (Cytotoxic Chemotherapy).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antithymocyte Globulin (Equine): Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Antithymocyte Globulin (Equine). Specifically, these effects may be unmasked if the dose of cytotoxic chemotherapy is reduced. Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Antithymocyte Globulin (Equine). Specifically, infections may occur with greater severity and/or atypical presentations. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Baricitinib: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Baricitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">BCG (Intravesical): Myelosuppressive Agents may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">BCG Products: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of BCG Products. Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of BCG Products. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brincidofovir: Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Brincidofovir. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brivudine: May enhance the adverse/toxic effect of Immunosuppressants (Cytotoxic Chemotherapy).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chikungunya Vaccine (Live): Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Chikungunya Vaccine (Live). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Chikungunya Vaccine (Live). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chloramphenicol (Ophthalmic): May enhance the adverse/toxic effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chloramphenicol (Systemic): Myelosuppressive Agents may enhance the myelosuppressive effect of Chloramphenicol (Systemic). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cladribine: May enhance the myelosuppressive effect of Myelosuppressive Agents.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cladribine: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Cladribine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">CloZAPine: Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically, the risk for neutropenia may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Coccidioides immitis Skin Test: Immunosuppressants (Cytotoxic Chemotherapy) may diminish the diagnostic effect of Coccidioides immitis Skin Test.  Management: Consider discontinuing cytotoxic chemotherapy several weeks prior to coccidioides immitis skin antigen testing to increase the likelihood of accurate diagnostic results.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (Adenovirus Vector): Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of COVID-19 Vaccine (Adenovirus Vector).  Management: Administer a 2nd dose using an mRNA COVID-19 vaccine (at least 4 weeks after the primary vaccine dose) and a bivalent booster dose (at least 2 months after the additional mRNA dose or any other boosters).<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (Inactivated Virus): Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of COVID-19 Vaccine (Inactivated Virus). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (mRNA): Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of COVID-19 Vaccine (mRNA).  Management: Give a 3-dose primary series for all patients aged 6 months and older taking immunosuppressive medications or therapies. Booster doses are recommended for certain age groups. See CDC guidance for details.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (Subunit): Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of COVID-19 Vaccine (Subunit). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (Virus-like Particles): Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of COVID-19 Vaccine (Virus-like Particles). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Deferiprone: Myelosuppressive Agents may enhance the neutropenic effect of Deferiprone.  Management: Avoid the concomitant use of deferiprone and myelosuppressive agents whenever possible. If this combination cannot be avoided, monitor the absolute neutrophil count more closely.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dengue Tetravalent Vaccine (Live): Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Dengue Tetravalent Vaccine (Live). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Dengue Tetravalent Vaccine (Live). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Denosumab: May enhance the immunosuppressive effect of Immunosuppressants (Cytotoxic Chemotherapy). Management: Consider the risk of serious infections versus the potential benefits of coadministration of denosumab and cytotoxic chemotherapy. If combined, monitor patients for signs/symptoms of serious infections.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Deucravacitinib: May enhance the immunosuppressive effect of Immunosuppressants (Cytotoxic Chemotherapy).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dipyrone: May enhance the adverse/toxic effect of Myelosuppressive Agents. Specifically, the risk for agranulocytosis and pancytopenia may be increased<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Efgartigimod Alfa: May diminish the therapeutic effect of Fc Receptor-Binding Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Etrasimod: May enhance the immunosuppressive effect of Immunosuppressants (Cytotoxic Chemotherapy).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fexinidazole: Myelosuppressive Agents may enhance the myelosuppressive effect of Fexinidazole. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Filgotinib: May enhance the immunosuppressive effect of Immunosuppressants (Cytotoxic Chemotherapy).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Inebilizumab: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Inebilizumab. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Influenza Virus Vaccines: Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Influenza Virus Vaccines.  Management: Administer influenza vaccines at least 2 weeks prior to initiating chemotherapy if possible. If vaccination occurs less than 2 weeks prior to or during chemotherapy, revaccinate at least 3 months after therapy discontinued if immune competence restored.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Irinotecan Products: May enhance the adverse/toxic effect of Sacituzumab Govitecan.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Leflunomide: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Leflunomide.  Management: Increase the frequency of chronic monitoring of platelet, white blood cell count, and hemoglobin or hematocrit to monthly, instead of every 6 to 8 weeks, if leflunomide is coadministered with immunosuppressive agents, such as cytotoxic chemotherapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lenograstim: Antineoplastic Agents may diminish the therapeutic effect of Lenograstim.  Management: Avoid the use of lenograstim 24 hours before until 24 hours after the completion of myelosuppressive cytotoxic chemotherapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lipegfilgrastim: Antineoplastic Agents may diminish the therapeutic effect of Lipegfilgrastim.  Management: Avoid concomitant use of lipegfilgrastim and myelosuppressive cytotoxic chemotherapy. Lipegfilgrastim should be administered at least 24 hours after the completion of myelosuppressive cytotoxic chemotherapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mitapivat: May decrease the serum concentration of UGT1A1 Substrates.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mumps- Rubella- or Varicella-Containing Live Vaccines: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Mumps- Rubella- or Varicella-Containing Live Vaccines. Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Mumps- Rubella- or Varicella-Containing Live Vaccines. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nadofaragene Firadenovec: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Nadofaragene Firadenovec. Specifically, the risk of disseminated adenovirus infection may be increased. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Natalizumab: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Natalizumab. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ocrelizumab: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Ocrelizumab. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ofatumumab: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Ofatumumab. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Olaparib: Myelosuppressive Agents may enhance the myelosuppressive effect of Olaparib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Palifermin: May enhance the adverse/toxic effect of Antineoplastic Agents. Specifically, the duration and severity of oral  mucositis may be increased. Management: Do not administer palifermin within 24 hours before, during infusion of, or within 24 hours after administration of myelotoxic chemotherapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pidotimod: Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Pidotimod. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pimecrolimus: May enhance the immunosuppressive effect of Immunosuppressants (Cytotoxic Chemotherapy).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pneumococcal Vaccines: Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Pneumococcal Vaccines. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Poliovirus Vaccine (Live/Trivalent/Oral): Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Poliovirus Vaccine (Live/Trivalent/Oral). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Poliovirus Vaccine (Live/Trivalent/Oral). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Polymethylmethacrylate: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the potential for allergic or hypersensitivity reactions to Polymethylmethacrylate.  Management: Use caution when considering use of bovine collagen-containing implants such as the polymethylmethacrylate-based Bellafill brand implant in patients who are receiving immunosuppressants. Consider use of additional skin tests prior to administration.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Promazine: May enhance the myelosuppressive effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rabies Vaccine: Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Rabies Vaccine.  Management: Complete rabies vaccination at least 2 weeks before initiation of immunosuppressant therapy if possible. If combined, check for rabies antibody titers, and if vaccination is for post exposure prophylaxis, administer a 5th dose of the vaccine.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ritlecitinib: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Ritlecitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ropeginterferon Alfa-2b: Myelosuppressive Agents may enhance the myelosuppressive effect of Ropeginterferon Alfa-2b.  Management: Avoid coadministration of ropeginterferon alfa-2b and other myelosuppressive agents. If this combination cannot be avoided, monitor patients for excessive myelosuppressive effects.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rozanolixizumab: May diminish the therapeutic effect of Fc Receptor-Binding Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ruxolitinib (Topical): Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Ruxolitinib (Topical). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sipuleucel-T: Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Sipuleucel-T.  Management: Consider reducing the dose or discontinuing the use of immunosuppressants, such as cytotoxic chemotherapy, prior to initiating sipuleucel-T therapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sphingosine 1-Phosphate (S1P) Receptor Modulator: May enhance the immunosuppressive effect of Immunosuppressants (Cytotoxic Chemotherapy).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tacrolimus (Topical): Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Tacrolimus (Topical). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Talimogene Laherparepvec: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Talimogene Laherparepvec. Specifically, the risk of infection from the live, attenuated herpes simplex virus contained in talimogene laherparepvec may be increased. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tertomotide: Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Tertomotide. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tofacitinib: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Tofacitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Typhoid Vaccine: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Typhoid Vaccine. Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Typhoid Vaccine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ublituximab: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Ublituximab. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">UGT1A1 Inducers: May decrease serum concentrations of the active metabolite(s) of Sacituzumab Govitecan. Specifically, concentrations of SN-38 may be decreased.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">UGT1A1 Inhibitors: May increase serum concentrations of the active metabolite(s) of Sacituzumab Govitecan. Specifically, concentrations of SN-38 may be increased.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Upadacitinib: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Upadacitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vaccines (Inactivated/Non-Replicating): Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Vaccines (Inactivated/Non-Replicating).  Management: Give inactivated vaccines at least 2 weeks prior to initiation of chemotherapy when possible. Patients vaccinated less than 14 days before initiating or during chemotherapy should be revaccinated at least 3 months after therapy is complete.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vaccines (Live): Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Vaccines (Live). Specifically, the risk of vaccine-associated infection may be increased. Vaccines (Live) may diminish the therapeutic effect of Immunosuppressants (Cytotoxic Chemotherapy). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Yellow Fever Vaccine: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Yellow Fever Vaccine. Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Yellow Fever Vaccine. <i> Risk X: Avoid combination</i></p></div>
<div class="block rep_considerations drugH1Div" id="F54363754"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;display:inline">Evaluate pregnancy status prior to use in patients who could become pregnant. Patients who could become pregnant should use effective contraception during therapy and for 6 months after the last sacituzumab govitecan dose. Patients with partners who could become pregnant should use effective contraception during therapy and for 3 months after the last dose of sacituzumab govitecan.</p></div>
<div class="block pri drugH1Div" id="F54363753"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Based on the mechanism of action, in utero exposure to sacituzumab govitecan may cause fetal harm.</p>
<p style="text-indent:0em;margin-top:2em;">Sacituzumab govitecan is composed of sacituzumab linked to SN-38. Sacituzumab is a humanized monoclonal antibody (IgG<sub>1</sub>). Placental transfer of human IgG is dependent upon the IgG subclass, maternal serum concentrations, newborn birth weight, and gestational age, generally increasing as pregnancy progresses. The lowest fetal IgG exposure would be expected during the period of organogenesis (Palmeira 2012; Pentsuk 2009). SN-38 is the genotoxic component.</p></div>
<div class="block brc drugH1Div" id="F54363755"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">It is not known if sacituzumab govitecan or SN-38 are present in breast milk.</p>
<p style="text-indent:-2em;margin-left:2em;">Due to the potential for serious adverse reactions in the breastfed infant, breastfeeding is not recommended by the manufacturer during therapy and for 1 month after the last sacituzumab govitecan dose.</p></div>
<div class="block mop drugH1Div" id="F54368241"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:-2em;margin-left:2em;">Monitor blood counts prior to dose on days 1 and 8 of each cycle and as clinically necessary (especially in patients known to be homozygous or heterozygous for UGT1A1*28). Evaluate pregnancy status prior to use in patients who could become pregnant. Monitor for neutropenic fever, hypersensitivity reactions, and infusion-related reactions (observe during and for at least 30 minutes after infusion). Monitor (including patient self-monitoring, after clear clinician instruction) for diarrhea, nausea, and vomiting, as well as a clinical indication for additional antiemetics and/or supportive measures (eg, fluids, electrolytes). Closely monitor for adverse reactions in patients with known reduced UGT1A1 activity.</p>
<p style="text-indent:-2em;margin-left:2em;">The American Society of Clinical Oncology hepatitis B virus (HBV) screening and management provisional clinical opinion (ASCO [Hwang 2020]) recommends HBV screening with hepatitis B surface antigen, hepatitis B core antibody, total Ig or IgG, and antibody to hepatitis B surface antigen prior to beginning (or at the beginning of) systemic anticancer therapy; do not delay treatment for screening/results. Detection of chronic or past HBV infection requires a risk assessment to determine antiviral prophylaxis requirements, monitoring, and follow-up.</p></div>
<div class="block pha drugH1Div" id="F54363786"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Sacituzumab govitecan is an antibody drug conjugate that consists of a humanized antitrophoblast cell-surface antigen 2 (Trop-2) monoclonal antibody coupled to the topoisomerase 1 inhibitor SN-38 via a cleavable linker (Bardia 2019). Trop-2 is a transmembrane glycoprotein that is highly expressed in many epithelial cancer cell surfaces (Tagawa 2021). TROP-2 is associated with cancer cell growth and has been detected in breast cancer cells (including triple-negative breast cancer cells). Sacituzumab govitecan binds to Trop-2 and is internalized; SN-38 is released in tumors both intracellularly and in the tumor microenvironment, leading to DNA damage, apoptosis, and cell death (Bardia 2019).</p></div>
<div class="block phk drugH1Div" id="F54363787"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Distribution: V<sub>dss</sub>: Sacituzumab govitecan: 3.6 L.</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: SN-38 (small molecule moiety of sacituzumab govitecan) is metabolized via UGT1A1.</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: Sacituzumab govitecan: 23.4 hours; free SN-38: 17.6 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Clearance: Sacituzumab govitecan: 0.13 L/hour.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F58216084"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Trodelvy</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Trodelvy</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Trodelvy</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Trodelvy</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Trodelvy</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Trodelvy</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Trodelvy</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Trodelvy</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Trodelvy</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Trodelvy</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Trodelvy</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Trodelvy</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Trodelvy</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Trodelvy</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Trodelvy</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Trodelvy</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Trodelvy</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Trodelvy</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Trodelvy</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Trodelvy</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Trodelvy</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Trodelvy</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-USP.1">
<a name="USP.1"></a>&lt;800&gt; Hazardous Drugs—Handling in Healthcare Settings. <i>United States Pharmacopeia and National Formulary </i>(USP 43-NF 38). Rockville, MD: United States Pharmacopeia Convention; 2020:74-92.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3960626">
<a name="3960626"></a>Alade SL, Brown RE, Paquet A Jr. Polysorbate 80 and E-Ferol toxicity. <i>Pediatrics</i>. 1986;77(4):5930597.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sacituzumab-govitecan-drug-information/abstract-text/3960626/pubmed" id="3960626" target="_blank">3960626</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33882206">
<a name="33882206"></a>Bardia A, Hurvitz SA, Tolaney SM, et al; ASCENT Clinical Trial Investigators. Sacituzumab govitecan in metastatic triple-negative breast cancer.<i> N Engl J Med.</i> 2021;384(16):1529-1541. doi:10.1056/NEJMoa2028485<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sacituzumab-govitecan-drug-information/abstract-text/33882206/pubmed" id="33882206" target="_blank">33882206</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30786188">
<a name="30786188"></a>Bardia A, Mayer IA, Vahdat LT, et al. Sacituzumab govitecan-hziy in refractory metastatic triple-negative breast cancer. <i>N Engl J Med</i>. 2019;380(8):741-751. doi:10.1056/NEJMoa1814213<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sacituzumab-govitecan-drug-information/abstract-text/30786188/pubmed" id="30786188" target="_blank">30786188</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6423951">
<a name="6423951"></a>Centers for Disease Control (CDC). Unusual syndrome with fatalities among premature infants: association with a new intravenous vitamin E product. <i>MMWR Morb Mortal Wkly Rep</i>. 1984;33(14):198-199.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sacituzumab-govitecan-drug-information/abstract-text/6423951/pubmed" id="6423951" target="_blank">6423951</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31584574">
<a name="31584574"></a>Fenn KM, Kalinsky K. Sacituzumab govitecan: antibody-drug conjugate in triple-negative breast cancer and other solid tumors. <i>Drugs Today (Barc)</i>. 2019;55(9):575-585. doi:10.1358/dot.2019.55.9.3039669<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sacituzumab-govitecan-drug-information/abstract-text/31584574/pubmed" id="31584574" target="_blank">31584574</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33939491">
<a name="33939491"></a>Griggs JJ, Bohlke K, Balaban EP, et al. Appropriate systemic therapy dosing for obese adult patients with cancer: ASCO guideline update. <i>J Clin Oncol</i>. 2021;39(18):2037-2048. doi:10.1200/JCO.21.00471<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sacituzumab-govitecan-drug-information/abstract-text/33939491/pubmed" id="33939491" target="_blank">33939491</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32716741">
<a name="32716741"></a>Hwang JP, Feld JJ, Hammond SP, et al. Hepatitis B virus screening and management for patients with cancer prior to therapy: ASCO provisional clinical opinion update. <i>J Clin Oncol</i>. 2020;38(31):3698-3715. doi:10.1200/JCO.20.01757<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sacituzumab-govitecan-drug-information/abstract-text/32716741/pubmed" id="32716741" target="_blank">32716741</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12534540">
<a name="12534540"></a>Isaksson M, Jansson L. Contact allergy to Tween 80 in an inhalation suspension. <i>Contact Dermatitis</i>. 2002;47(5):312-313. doi:10.1034/j.1600-0536.2002.4705104.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sacituzumab-govitecan-drug-information/abstract-text/12534540/pubmed" id="12534540" target="_blank">12534540</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10985636">
<a name="10985636"></a>Lucente P, Iorizzo M, Pazzaglia M. Contact sensitivity to Tween 80 in a child. <i>Contact Dermatitis</i>. 2000;43(3):172.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sacituzumab-govitecan-drug-information/abstract-text/10985636/pubmed" id="10985636" target="_blank">10985636</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-NIOSH.1">
<a name="NIOSH.1"></a>National Institute for Occupational Safety and Health (NIOSH) notice. Centers for Disease Control and Prevention website. <a href="https://www.cdc.gov/niosh/docs/2016-161/default.html" target="_blank">https://www.cdc.gov/niosh/docs/2016-161/default.html</a>. Updated May 12, 2020. Accessed May 22, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28558150">
<a name="28558150"></a>Ocean AJ, Starodub AN, Bardia A, et al. Sacituzumab govitecan (IMMU-132), an anti-Trop-2-SN-38 antibody-drug conjugate for the treatment of diverse epithelial cancers: safety and pharmacokinetics. <i>Cancer</i>. 2017;123(19):3843-3854. doi:10.1002/cncr.30789<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sacituzumab-govitecan-drug-information/abstract-text/28558150/pubmed" id="28558150" target="_blank">28558150</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22235228">
<a name="22235228"></a>Palmeira P, Quinello C, Silveira-Lessa AL, Zago CA, Carneiro-Sampaio M. IgG placental transfer in healthy and pathological pregnancies. <i>Clin Dev Immunol</i>. 2012;2012:985646. doi:10.1155/2012/985646<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sacituzumab-govitecan-drug-information/abstract-text/22235228/pubmed" id="22235228" target="_blank">22235228</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19626656">
<a name="19626656"></a>Pentsuk N, van der Laan JW. An interspecies comparison of placental antibody transfer: new insights into developmental toxicity testing of monoclonal antibodies. <i>Birth Defects Res B Dev Reprod Toxicol</i>. 2009;86(4):328-344. doi:10.1002/bdrb.20201<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sacituzumab-govitecan-drug-information/abstract-text/19626656/pubmed" id="19626656" target="_blank">19626656</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-37633306">
<a name="37633306"></a>Rugo HS, Bardia A, Marmé F, et al. Overall survival with sacituzumab govitecan in hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer (TROPiCS-02): a randomised, open-label, multicentre, phase 3 trial. <i>Lancet</i>. 2023;402(10411):1423-1433. doi:10.1016/S0140-6736(23)01245-X<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sacituzumab-govitecan-drug-information/abstract-text/37633306/pubmed" id="37633306" target="_blank">37633306</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36027558">
<a name="36027558"></a>Rugo HS, Bardia A, Marmé F, et al; TROPiCS-02 Study Investigators. Sacituzumab govitecan in hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer. <i>J Clin Oncol</i>. 2022:JCO2201002. doi:10.1200/JCO.22.01002<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sacituzumab-govitecan-drug-information/abstract-text/36027558/pubmed" id="36027558" target="_blank">36027558</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7746084">
<a name="7746084"></a>Shelley WB, Talanin N, Shelley ED. Polysorbate 80 hypersensitivity. <i>Lancet</i>. 1995;345(8960):1312-1313. doi:10.1016/s0140-6736(95)90963-x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sacituzumab-govitecan-drug-information/abstract-text/7746084/pubmed" id="7746084" target="_blank">7746084</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33929895">
<a name="33929895"></a>Tagawa ST, Balar AV, Petrylak DP, et al. TROPY-U-01: a phase II open-label study of sacituzumab govitecan in patients with metastatic urothelial carcinoma progressing after platinum-based chemotherapy and checkpoint inhibitors. <i>J Clin Oncol. </i>2021;39(22):2474-2485. doi:10.1200/JCO.20.03489<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sacituzumab-govitecan-drug-information/abstract-text/33929895/pubmed" id="33929895" target="_blank">33929895</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Trodelvy.1">
<a name="Trodelvy.1"></a>Trodelvy (sacituzumab govitecan) [prescribing information]. Foster City, CA: Gilead Sciences Inc; February 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-NIOSH.2">
<a name="NIOSH.2"></a>US Department of Health and Human Services; Centers for Disease Control and Prevention; National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2016. <a href="https://www.cdc.gov/niosh/docs/2016-161/default.html" target="_blank">https://www.cdc.gov/niosh/docs/2016-161/default.html</a>. Updated September 2016. Accessed May 22, 2020.</div>
</li></ol></div><div id="topicVersionRevision">Topic 127999 Version 107.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
